Roel van den Akker

Four pharma experts discuss industry trends in M&A, direct-to-patient sales, patient access and commercial strategy at the H1 midyear mark.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Four pharma commerce voices check back in at the midpoint of 2026 to see how their dealmaking, patient access and commercialization predictions have held up.

PwC's Roel van den Akker says pharma M&A ran beyond expectations in the first half of 2026, with dealmaking potentially on pace to hit $300 billion in H2.

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.